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Books exposing the misdeeds of the pharmaceutical industry are so common these days that pharma–bashing has
become a genre unto itself. Especially in the realm of psychopharmacology, the pharmaceutical industry has given
us plenty of grist for shocking exposes and scathing critiques. I call attention to this body of literature in order to
say: Do not assume that Robert Whitaker’s book, Anatomy
of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America, is just another
anti–psychopharm diatribe.
Granted, Whitaker is no fan of the pharmaceutical industry. But his book is an attempt to make a very specific and
novel point about current psychiatric treatments, a point
that can be stated entirely independently of the politics of
big pharma and psychiatry. Whitaker’s thesis is that mental
illness has become more prevalent since the 1950s biological
revolution in psychiatry, and that modern psychiatric drugs
are to blame.
Specifically, he argues that our current psychiatric medications are actually causing patients to develop more severe
and chronic forms of mental illness. Furthermore, he maintains that this is the case for virtually all illnesses, from
mood disorders and anxiety to schizophrenia. He grants
that some medications may help patients initially (while
maintaining that others are no better than placebo in the
short run). However, it is not the initial therapeutic effects,
or lack thereof, that principally concern him. It is the long–
term effects of these drugs. His thesis is that our brains are irreversibly changed by psychiatric medications in ways that
turn episodic and potentially manageable disorders into
chronic and severe disabilities.
The idea sounds wildly implausible. The drugs are not
just ineffective, but damaging? Irreparably so? Not just one
class of drugs, but most of them? And the experts failed to
notice these facts? But let’s set aside the question of whether
it’s true for a moment, and agree on this much: If his hypothesis were true, then it would be a matter of extraordi-

nary public health importance. If the hypothesis were even
somewhat plausible, given Whitaker’s evidence, then it’s
an urgent and immensely important neuroethical issue, one
that we should take seriously and get busy investigating
further.
So how persuasive is Whitaker’s evidence? No single
book, let alone a book written by a journalist for laymen, is
going to settle an issue as enormous as this one. This issue, in
particular, comes with built–in challenges. Research projects
using randomized experimental assignment to drug versus
placebo do not follow patients over periods of years, so
we lack the most decisive kind of evidence on the question
of long–term iatrogenic effects. In the absence of experimental evidence, Whitaker turns to a variety of sources of
observational evidence, examining the correlation between
treatments administered to patients and their long–term
outcomes. Of course, sicker patients are more likely to be
medicated in the first place, a confound that would lead us
to expect worse outcomes after medication even if medication does not cause the worse outcomes. To a certain extent
such confounds can be corrected for statistically, but this is
never foolproof and in most cases was not even attempted.
Whitaker also takes a quasi–experimental approach, comparing patient outcomes across decades (before and after
the biological revolution in psychiatry) or countries (which
vary in their use of psychiatric medications). These comparisons offer a clever way to approximate the design of a
long–term experimental study, but they have confounds of
their own because of differences in the broader social and
medical contexts of patient care at different times and in
different societies.
I wish that Whitaker acknowledged the limitations of
the studies he cites more explicitly. Although he does note
the problems just mentioned at various points in the book,
he also loses sight of them at times. Take this footnote, for
example: “The caveat with the naturalistic studies is that
the unmedicated cohort, at the moment of initial diagnosis,
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may not be as depressed as those who go on the drugs. Furthermore, those who eschew drugs may also have greater
“inner resilience.” Even given these caveats, we should be
able to gain a sense of the course of unmedicated depression
from the naturalistic studies, and see how it compares to the
course of depression treated with antidepressants (p. 164).
But if we don’t know whether the medicated and unmedicated cohorts differed from the beginning, then how can we
use a comparison of their long–term outcomes to gain any
sense of anything?
The dearth of strong evidence available on the long–
term effects of psychiatric medications, and Whitaker’s occasional lapses of objectivity in data interpretation, make it
impossible to draw firm conclusions. Of course, where new
hypotheses concerning public health are concerned, firm
conclusions are invariably more of a goal than a reality. I
believe Whitaker has succeeded in proposing a hypothesis
of potentially great importance and providing at least some
degree of support for it. At a minimum, he has highlighted
how little we know about the long–term effects of treatment
with psychiatric medications. This in itself is an important
point.
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I would have preferred fewer patient vignettes, but understand that a trade book needs to place the facts and 105
figures of epidemiology and clinical trials into a human
context. I also would have preferred less criticism of the
psychiatry establishment and the pharmaceutical industry,
not out of concern for either, but because it turns off so many
of the people who should be reading this book.
110
Overall, I found Whitaker’s book extremely thoughtprovoking. His case is based on circumstantial evidence,
because this is the only kind of evidence we have. He
shows that a large amount of such evidence is consistent
with the long–term exacerbation of mental illness by psy- 115
chiatric medications. It is a “connecting-the-dots” kind of
argument, and could of course be mistaken. And this raises
the questions:
Is Whitaker mistaken?
How would we know?
And, in a society where substantial fractions of the adult
and child population are using psychiatric medications,
why do we not have better evidence concerning long–term
effects?
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